Diabetes mellitus and risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition

International Journal of Cancer

Volumn 136, Issue 2, 2015, Pages 372-381

  Tsilidis, Konstantinos K ^a,b   Allen, Naomi E ^c   Appleby, Paul N ^a   Rohrmann, Sabine ^d   Nöthlings, Ute ^e   Arriola, Larraitz ^f,g   Gunter, Marc J ^h   Chajes, Veronique ⁱ   Rinaldi, Sabina ⁱ   Romieu, Isabelle ⁱ   Murphy, Neil ^h   Riboli, Elio ^h   Tzoulaki, Ioanna ^b,h   Kaaks, Rudolf ^j   Lukanova, Annekatrin ^j,k   Boeing, Heiner ^l   Pischon, Tobias ^l,m   Dahm, Christina C ⁿ   Overvad, Kim ^n,o   Quirõs, J Ramõn ^p   Fonseca Nunes, Ana ^q   Molina Montes, Esther ^f,r,s   Gavrila Chervase, Diana ^f,t   Ardanaz, Eva ^f,u   Khaw, Kay T ^v   Wareham, Nick J ^w   Roswall, Nina ^x   Tjønneland, Anne ^x   Lagiou, Pagona ^y,z,aa   Trichopoulos, Dimitrios ^z,aa,ab   Trichopoulou, Antonia ^y,ab   Palli, Domenico ^ac   Pala, Valeria ^ad   Tumino, Rosario ^ae   Vineis, Paolo ^h,af   Bueno De Mesquita, H Bas ^h,ag,ah   Malm, Johan ^ai   Orho Melander, Marju ^aj   Johansson, Mattias ^i,k   Stattin, Pär ^k   Travis, Ruth C ^a   Key, Timothy J ^a   more..

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF IOANNINA   (Greece)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITY OF ZURICH   (Switzerland)

^e UNIVERSITY OF BONN   (Germany)

^f CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^g BIODONOSTIA HEALTH RESEARCH INSTITUTE   (Spain)

^h IMPERIAL COLLEGE LONDON   (United Kingdom)

ⁱ INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^j GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^k UMEÅ UNIVERSITY   (Sweden)

^l GERMAN INSTITUTE OF HUMAN NUTRITION   (Germany)

^m MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

ⁿ AARHUS UNIVERSITY   (Denmark)

^o AALBORG UNIVERSITY HOSPITAL   (Denmark)

^p Public Health Directorate   (Spain)

^q CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^r ANDALUSIAN SCHOOL OF PUBLIC HEALTH   (Spain)

^s Granada Health Research Institute ibs GRANADA   (Spain)

^t DEPARTMENT OF EPIDEMIOLOGY   (Spain)

^u INSTITUTO DE SALUD PÚBLICA DE NAVARRA   (Spain)

^v UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^w MRC EPIDEMIOLOGY UNIT   (United Kingdom)

^x DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^y UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^z HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^aa BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^ab HELLENIC HEALTH FOUNDATION   (Greece)

^ac CANCER RESEARCH AND PREVENTION INSTITUTE ISPO   (Italy)

^ad NATIONAL CANCER INSTITUTE   (Italy)

^ae CIVILE M P AREZZO HOSPITAL   (Italy)

^af Human Genetics Foundation   (Italy)

^ag NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^ah UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^ai LUND UNIVERSITY   (Sweden)

^aj LUND UNIVERSITY HOSPITAL   (Sweden)

more..

Author keywords

androgens; cohort study; insulin like growth factor proteins; prostate cancer; type 2 diabetes

Indexed keywords

ANDROGEN; ANDROSTANEDIOL; ANDROSTANEDIOL GLUCURONIDE; ANDROSTENEDIONE; SEX HORMONE BINDING GLOBULIN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; TESTOSTERONE; UNCLASSIFIED DRUG; SOMATOMEDIN BINDING PROTEIN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER RISK; CANCER STAGING; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE DURATION; FOLLOW UP; HORMONE DETERMINATION; HUMAN; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT; SELF REPORT; BLOOD; BODY MASS; CLINICAL TRIAL; COMPLICATION; EUROPE; INCIDENCE; MIDDLE AGED; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRITIONAL STATUS; PATHOPHYSIOLOGY; PROGNOSIS; PROSPECTIVE STUDY; PROSTATIC NEOPLASMS; RISK FACTOR;

ADULT; AGED; ANDROGENS; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; EUROPE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; NUTRITIONAL STATUS; PROGNOSIS; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RISK FACTORS; TESTOSTERONE;

EID: 84926642161     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28989     Document Type: Article

References (43)

1. American Cancer Society. Global cancer facts and figures 2007. American Cancer Society, Atlanta, GA 2007.
2. Vigneri P, Frasca F, Sciacca L, et al., Diabetes and cancer. Endocr Relat Cancer 2009; 16: 1103-23.
3. Kasper JS, Giovannucci E,. A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2006; 15: 2056-62.
4. Bansal D, Bhansali A, Kapil G, et al., Type 2 diabetes and risk of prostate cancer: a meta-analysis of observational studies. Prostate Cancer Prostatic Dis 2013; 16: 151-8.
5. Pierce BL,. Why are diabetics at reduced risk for prostate cancer? A review of the epidemiologic evidence. Urol Oncol 2012; 30: 735-43.
6. Riboli E, Hunt KJ, Slimani N, et al., European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. Public Health Nutr 2002; 5: 1113-24.
7. Sluik D, Boeing H, Montonen J, et al., Associations between general and abdominal adiposity and mortality in individuals with diabetes mellitus. Am J Epidemiol 2011; 174: 22-34.
8. Sodergard R, Backstrom T, Shanbhag V, et al., Calculation of free and bound fractions of testosterone and estradiol-17 beta to human plasma proteins at body temperature. J Steroid Biochem 1982; 16: 801-10.
9. Travis RC, Key TJ, Allen NE, et al., Serum androgens and prostate cancer among 643 cases and 643 controls in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer 2007; 121: 1331-8.
10. Allen NE, Key TJ, Appleby PN, et al., Serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 concentrations and prostate cancer risk: results from the European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiol Biomarkers Prev 2007; 16: 1121-7.
11. Gong Z, Neuhouser ML, Goodman PJ, et al., Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev 2006; 15: 1977-83.
12. Li Q, Kuriyama S, Kakizaki M, et al., History of diabetes mellitus and the risk of prostate cancer: the Ohsaki Cohort Study. Cancer Causes Control 2010; 21: 1025-32.
13. Tseng CH,. Diabetes and risk of prostate cancer: a study using the National Health Insurance. Diabetes Care 2011; 34: 616-21.
14. Lee MY, Lin KD, Hsiao PJ, et al., The association of diabetes mellitus with liver, colon, lung, and prostate cancer is independent of hypertension, hyperlipidemia, and gout in Taiwanese patients. Metabolism 2012; 61: 242-9.
15. Wu C, Moreira DM, Gerber L, et al., Diabetes and prostate cancer risk in the REDUCE trial. Prostate Cancer Prostatic Dis 2011; 14: 326-31.
16. Kasper JS, Liu Y, Giovannucci E,. Diabetes mellitus and risk of prostate cancer in the health professionals follow-up study. Int J Cancer 2009; 124: 1398-403.
17. Calton BA, Chang SC, Wright ME, et al., History of diabetes mellitus and subsequent prostate cancer risk in the NIH-AARP Diet and Health Study. Cancer Causes Control 2007; 18: 493-503.
18. Zhu K, Lee IM, Sesso HD, et al., History of diabetes mellitus and risk of prostate cancer in physicians. Am J Epidemiol 2004; 159: 978-82.
19. Atchison EA, Gridley G, Carreon JD, et al., Risk of cancer in a large cohort of U.S. veterans with diabetes. Int J Cancer 2011; 128: 635-43.
20. Fall K, Garmo H, Gudbjornsdottir S, et al., Diabetes mellitus and prostate cancer risk; a nationwide case-control study within PCBaSe Sweden. Cancer Epidemiol Biomarkers Prev 2013; 22: 1102-9.
21. Gudmundsson J, Sulem P, Steinthorsdottir V, et al., Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat Genet 2007; 39: 977-83.
22. Machiela MJ, Lindstrom S, Allen NE, et al., Association of type 2 diabetes susceptibility variants with advanced prostate cancer risk in the Breast and Prostate Cancer Cohort Consortium. Am J Epidemiol 2012; 176: 1121-9.
23. Waters KM, Wilkens LR, Monroe KR, et al., No association of type 2 diabetes risk variants and prostate cancer risk: the multiethnic cohort and PAGE. Cancer Epidemiol Biomarkers Prev 2011; 20: 1979-81.
24. Ding EL, Song Y, Malik VS, et al., Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2006; 295: 1288-99.
25. Roddam AW, Allen NE, Appleby P, et al., Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst 2008; 100: 170-83.
26. Robinson D, Garmo H, Bill-Axelson A, et al., Use of 5alpha-reductase inhibitors for lower urinary tract symptoms and risk of prostate cancer in Swedish men: nationwide, population based case-control study. BMJ 2013; 346: f3406.
27. Giovannucci E, Michaud D,. The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas. Gastroenterology 2007; 132: 2208-25.
28. Roddam AW, Allen NE, Appleby P, et al., Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. Ann Intern Med 2008; 149: 461-71, W83-8.
29. Rajpathak SN, He M, Sun Q, et al., Insulin-like growth factor axis and risk of type 2 diabetes in women. Diabetes 2012; 61: 2248-54.
30. Turner EL, Lane JA, Donovan JL, et al., Association of diabetes mellitus with prostate cancer: nested case-control study (Prostate testing for cancer and treatment study). Int J Cancer 2011; 128: 440-6.
31. Leitzmann MF, Ahn J, Albanes D, et al., Diabetes mellitus and prostate cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Causes Control 2008; 19: 1267-76.
32. Xu H, Jiang HW, Ding GX, et al., Diabetes mellitus and prostate cancer risk of different grade or stage: A systematic review and meta-analysis. Diabetes Res Clin Pract 2013; 99: 241-9.
33. Buzzai M, Jones RG, Amaravadi RK, et al., Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 2007; 67: 6745-52.
34. Stevens RJ, Ali R, Bankhead CR, et al., Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials. Diabetologia 2012; 55: 2593-603.
35. Zhang P, Li H, Tan X, et al., Association of metformin use with cancer incidence and mortality: a meta-analysis. Cancer Epidemiol 2013; 37: 207-18.
36. Patel SM, Iqbal N, Kaul S, et al., Effects of metformin and leuprolide acetate on insulin resistance and testosterone levels in nondiabetic postmenopausal women: a randomized, placebo-controlled trial. Fertil Steril 2010; 94: 2161-6.
37. Sarma AV, Burke JP, Jacobson DJ, et al., Associations between diabetes and clinical markers of benign prostatic hyperplasia among community-dwelling Black and White men. Diabetes Care 2008; 31: 476-82.
38. Sarma AV, Parsons JK, McVary K, et al., Diabetes and benign prostatic hyperplasia/lower urinary tract symptoms-what do we know? J Urol 2009; 182: S32-7.
39. Werny DM, Saraiya M, Gregg EW,. Prostate-specific antigen values in diabetic and nondiabetic US men, 2001-2002. Am J Epidemiol 2006; 164: 978-83.
40. Waters KM, Henderson BE, Stram DO, et al., Association of diabetes with prostate cancer risk in the multiethnic cohort. Am J Epidemiol 2009; 169: 937-45.
41. Okura Y, Urban LH, Mahoney DW, et al., Agreement between self-report questionnaires and medical record data was substantial for diabetes, hypertension, myocardial infarction and stroke but not for heart failure. J Clin Epidemiol 2004; 57: 1096-103.
42. Bansal D, Undela K, D'Cruz S, et al., Statin use and risk of prostate cancer: a meta-analysis of observational studies. PLoS One 2012; 7: e46691.
43. Lehman DM, Lorenzo C, Hernandez J, et al., Statin use as a moderator of metformin effect on risk for prostate cancer among type 2 diabetic patients. Diabetes Care 2012; 35: 1002-7.